Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Risperdal (risperidone) Consta Clear all
Completed Phase 3 Interventional Results available

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

NCT00589914
View directory record Official record
Conditions
Schizophrenia
Interventions
RISPERDAL CONSTA, Paliperidone palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Results available

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

NCT00571688
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperdal (risperidone) Consta, Treatment as usual
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 4 Interventional

Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

NCT00215579
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Depot Risperidone Microsphere (Consta)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Butner, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 24, 2026, 7:49 AM EDT
Terminated Phase 4 Interventional Results available

Optimizing Response in Psychosis Study

NCT00314327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Brooklyn, New York • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

NCT00132678
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperdal Consta, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Little Rock, Arkansas • La Mesa, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Not applicable Interventional

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

NCT00845572
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Consta Club
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

Bioavailability of LY03004 and Risperdal® Consta®

NCT02091388
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LY03004, Risperdal® Consta®
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

NCT01150448
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Cerritos, California • National City, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 24, 2026, 7:49 AM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

NCT02472652
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Abilify Maintena
Drug
Lead sponsor
Gazda, Thomas D., M.D., PC
Individual
Eligibility
18 Years to 40 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bullhead City, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 24, 2026, 7:49 AM EDT
Completed No phase listed Observational

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)

NCT00246194
View directory record Official record
Conditions
Schizophrenia
Interventions
risperidone (RISPERDAL CONSTA)
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 24, 2026, 7:49 AM EDT
Completed No phase listed Observational

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

NCT01181960
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users, Other Antipsychotics - New Starts
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Bullhead City, Arizona • Colton, California • Imperial, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 3 Interventional

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

NCT00148083
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal Consta (drug), Social Skills Training
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • White Plains, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 24, 2026, 7:49 AM EDT
Completed No phase listed Observational

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

NCT03919994
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
57
States / cities
Tucson, Arizona • Costa Mesa, California • El Cajon, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Results available

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

NCT00130923
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
Interventions
Risperidone Long Acting, oral risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Miami, Florida • Kansas City, Missouri • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02186769
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal® Consta®, LY03004
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Orange County, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 24, 2026, 7:49 AM EDT
Terminated Phase 4 Interventional

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCT00314613
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic/Risperidone Consta
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

Risperdal Consta for Bipolar Disorder

NCT00177164
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Injectable Risperidone (Consta) or oral antipsychotic
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence

NCT00385801
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Risperidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 24, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 24, 2026, 7:49 AM EDT